MCID: NRV006
MIFTS: 56

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 73
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 73
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 44
Nervous System--Cancer 73
Nervous System Tumor 55
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 35 192 192.9
MeSH 44 D009380
NCIt 50 C35562

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to autonomic nervous system neoplasm and central nervous system cancer. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are ERK Signaling and Cell Cycle, Mitotic. The drugs Tramadol and Morphine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Benign Neoplasm Nervous System Benign Neoplasm
Central Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 34.2 BACE1 CASP3 MYCN TP53
2 central nervous system cancer 34.0 CDKN2A IDH1 KMT2D MGMT MYCN NF1
3 peripheral nervous system neoplasm 31.8 BACE1 CASP3 MYCN NF1 NF2 TP53
4 oligodendroglioma 31.8 CDKN2A CDKN2B IDH1 MGMT TP53
5 ewing sarcoma 31.6 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN
6 brain cancer 31.4 CASP3 CDK4 IDH1 KMT2D MGMT MYCN
7 pleomorphic xanthoastrocytoma 30.3 IDH1 MGMT TP53
8 ependymoma 30.2 MGMT NF2 RB1
9 neurofibromatosis, type iv, of riccardi 30.2 CDKN2B-AS1 NF1 NF2
10 neurofibroma 30.1 CDKN2A NF1 NF2
11 meningioma, familial 30.0 CDKN2A NF1 NF2 SST TP53
12 glioma 29.9 CCND1 CDK4 CDKN2A CDKN2B-AS1 IDH1 NF1
13 spindle cell lipoma 29.8 CDK4 RB1
14 medulloblastoma 29.7 CASP3 CCND1 CDK4 CDKN2B CDKN2B-AS1 IDH1
15 olfactory neural tumor 12.1
16 glioma susceptibility 1 11.1
17 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.1
18 mismatch repair cancer syndrome 11.1
19 neuroblastoma 11.0
20 glioma susceptibility 2 11.0
21 glioma susceptibility 3 11.0
22 glioma susceptibility 9 11.0
23 central nervous system hematologic cancer 11.0
24 central neurocytoma 10.9
25 neurilemmomatosis 10.9
26 ectomesenchymoma 10.9
27 malignant ectomesenchymoma 10.9
28 schwannomatosis 1 10.9
29 central nervous system primitive neuroectodermal neoplasm 10.9
30 central nervous system sarcoma 10.9
31 cranial nerve malignant neoplasm 10.9
32 central nervous system germ cell tumor 10.9
33 central nervous system melanocytic neoplasm 10.9
34 central nervous system mesenchymal non-meningothelial tumor 10.9
35 spinal cancer 10.9
36 gliofibroma 10.4 NF1 TP53
37 vulvar adenocarcinoma 10.4 RB1 TP53
38 non-hereditary retinoblastoma 10.4 MYCN RB1
39 plexiform neurofibroma 10.4 CDKN2B-AS1 NF1 NF2
40 male reproductive system disease 10.4 CASP3 CCND1 TP53
41 ring chromosome 7 10.4 CDK4 TP53
42 neurofibromatosis, familial spinal 10.4 NF1 NF2
43 amyloid tumor 10.4 NF1 NF2 TUBB3
44 malignant glandular tumor of peripheral nerve sheath 10.4 NF1 SST
45 short-rib thoracic dysplasia 4 with or without polydactyly 10.4 CASP3 TP53
46 liposarcoma 10.4 CDK4 CDKN2A TP53
47 scrotal carcinoma 10.4 CDKN2A CDKN2B TP53
48 nervous system benign neoplasm 10.4 NF1 NF2 TP53
49 small cell sarcoma 10.4 CDK4 NF2 TP53
50 cerebral convexity meningioma 10.4 NF2 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

26 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.03 RB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.03 MGMT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.03 RB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.03 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.03 RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.03 CCND1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.03 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.03 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.03 RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.03 CCND1 RB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.03 CCND1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.03 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.03 CCND1 MGMT RB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.03 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.03 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.03 MGMT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.03 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.03 MGMT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.03 RB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.03 RB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.03 MGMT
22 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 CDK2 CDKN2A RB1 SST TP53
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CASP3 CCND1 CDK2 CDKN2A RB1 SST

MGI Mouse Phenotypes related to Nervous System Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.51 BACE1 BCHE CASP3 CCND1 CDK2 CDK4
2 mortality/aging MP:0010768 10.49 BACE1 BCHE CASP3 CCND1 CDK2 CDK4
3 cellular MP:0005384 10.46 BACE1 CASP3 CCND1 CDK2 CDK4 CDKN2A
4 growth/size/body region MP:0005378 10.46 BACE1 CASP3 CCND1 CDK2 CDK4 CDKN2A
5 behavior/neurological MP:0005386 10.44 BACE1 CASP3 CCND1 CDK4 CDKN2A KMT2D
6 immune system MP:0005387 10.39 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
7 hematopoietic system MP:0005397 10.38 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
8 endocrine/exocrine gland MP:0005379 10.37 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
9 cardiovascular system MP:0005385 10.36 CASP3 CCND1 CDK2 CDK4 CDKN2A KMT2D
10 integument MP:0010771 10.31 BACE1 CASP3 CCND1 CDK2 CDK4 CDKN2A
11 digestive/alimentary MP:0005381 10.3 CASP3 CCND1 CDK4 CDKN2A MYCN NF1
12 embryo MP:0005380 10.3 CDK2 CDK4 CDKN2A KMT2D MYCN NF1
13 nervous system MP:0003631 10.3 BACE1 CASP3 CCND1 CDK4 CDKN2A KMT2D
14 craniofacial MP:0005382 10.26 CASP3 CCND1 KMT2D MYCN NF1 NF2
15 neoplasm MP:0002006 10.26 CCND1 CDK2 CDK4 CDKN2A CDKN2B KMT2D
16 muscle MP:0005369 10.24 BACE1 CASP3 CDK2 CDK4 CDKN2A KMT2D
17 liver/biliary system MP:0005370 10.18 CDK2 CDK4 CDKN2A MYCN NF1 NF2
18 no phenotypic analysis MP:0003012 10.13 BACE1 CASP3 CDKN2A CDKN2B MGMT MYCN
19 hearing/vestibular/ear MP:0005377 10.12 CASP3 KMT2D NF1 NF2 RB1 RBL1
20 normal MP:0002873 10.06 BACE1 CCND1 CDK4 MYCN NF1 RB1
21 reproductive system MP:0005389 10.03 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
22 renal/urinary system MP:0005367 9.97 CASP3 CDK4 CDKN2B MYCN NF1 NF2
23 respiratory system MP:0005388 9.97 CASP3 CCND1 CDKN2A IDH1 KMT2D MGMT
24 pigmentation MP:0001186 9.85 CASP3 CDK4 CDKN2A NF1 RB1 TP53
25 skeleton MP:0005390 9.73 CASP3 CCND1 CDKN2A IDH1 KMT2D MYCN
26 vision/eye MP:0005391 9.36 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 703)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Morphine Approved, Investigational Phase 4,Phase 2,Not Applicable 57-27-2 5288826
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
4
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
6
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-03-3
7
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
9
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
10
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
11
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
12
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83150-76-9 383414 6400441
16
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
17
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
18
Thrombin Approved, Investigational Phase 4
19
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
20
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
21
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
22
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
23
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
24
Ibuprofen Approved Phase 4 15687-27-1 3672
25
Clevidipine Approved, Investigational Phase 4 167221-71-8
26
Labetalol Approved Phase 4 36894-69-6 3869
27
Hydralazine Approved Phase 4 86-54-4 3637
28
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
30 Piracetam Approved, Investigational Phase 4,Phase 2,Not Applicable 7491-74-9
31
Mitoxantrone Approved, Investigational Phase 4,Phase 1 65271-80-9 4212
32
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
33
Lidocaine Approved, Vet_approved Phase 4,Phase 1 137-58-6 3676
34
Sulfamethoxazole Approved Phase 4,Phase 1 723-46-6 5329
35
Trimethoprim Approved, Vet_approved Phase 4,Phase 1 738-70-5 5578
36
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
37
Pasireotide Approved Phase 4,Phase 2,Phase 3 396091-73-9 9941444
38
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
39
Cefdinir Approved Phase 4 91832-40-5 6915944
40
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
41
Cefazolin Approved Phase 4 25953-19-9 656510 33255
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
43
Glutamic Acid Approved, Nutraceutical Phase 4,Not Applicable 56-86-0 33032
44 Etiracetam Investigational Phase 4,Phase 1,Phase 2,Not Applicable 33996-58-6
45
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
46 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
49 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
50 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1914)
# Name Status NCT ID Phase Drugs
1 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
3 Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis Unknown status NCT02590510 Phase 4 methotrexate
4 Cavernous Sinus Dissection and Bleeding in Meningiomas Unknown status NCT02863484 Phase 4
5 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
6 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
7 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
8 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
9 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
10 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
11 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
12 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
13 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
14 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
15 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
16 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
17 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
18 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
19 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
20 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
21 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
22 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
23 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
24 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
25 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
26 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
27 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
28 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
29 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
30 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
31 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
32 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
33 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
34 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
35 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
36 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
37 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
40 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
41 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
42 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
43 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
44 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
45 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
46 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
47 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Local Radiotherapy Following Complete Resection of a Brain Metastasis Unknown status NCT02729558 Phase 3
50 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection Unknown status NCT01535209 Phase 3

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

MalaCards organs/tissues related to Nervous System Cancer:

41
Brain, Liver, Lung, Skin, Bone, Tongue, Cervix

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

19
The Nervous System

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 28)
# Title Authors Year
1
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. ( 29374660 )
2018
2
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. ( 30350913 )
2018
3
Exosomes impact survival to radiation exposure in cell line models of nervous system cancer. ( 30546829 )
2018
4
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
5
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. ( 30034079 )
2017
6
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
7
Stat Bite Number of New Brain and Other Nervous System Cancer Cases By Race/Ethnicity & Sex (2008-2012). ( 26538626 )
2015
8
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
9
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
10
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
11
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
12
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
13
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
14
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
15
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
16
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
17
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
18
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
19
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
20
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
21
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
22
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
23
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
24
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
25
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
26
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
27
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
28
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
2
Show member pathways
13.46 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
3
Show member pathways
13.15 CDK2 CDK4 CDKN2A CDKN2B RB1 TP53
4
Show member pathways
13.11 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
5
Show member pathways
13.06 CASP3 CCND1 CDK2 CDK4 RB1 RBL1
6
Show member pathways
12.94 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
7 12.9 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
8
Show member pathways
12.84 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
9
Show member pathways
12.81 CCND1 CDK2 CDK4 CDKN2A CDKN2B NF1
10
Show member pathways
12.8 CASP3 CCND1 CDK2 CDK4 TP53
11
Show member pathways
12.73 CASP3 CCND1 CDK2 CDK4 MGMT RB1
12 12.62 BACE1 MYCN NF1 NF2 TUBB3
13
Show member pathways
12.58 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
14 12.56 CCND1 CDK2 CDK4 CDKN2A MGMT RB1
15 12.52 CCND1 CDK2 CDK4 RB1 RBL1 TP53
16 12.51 CCND1 CDK4 CDKN2A CDKN2B RB1 TP53
17
Show member pathways
12.46 CCND1 CDK2 CDK4 CDKN2A CDKN2B KMT2D
18
Show member pathways
12.43 CCND1 CDK2 CDK4 RB1
19
Show member pathways
12.39 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
20 12.38 CASP3 CCND1 CDK2 CDK4 RB1 TP53
21 12.37 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
22
Show member pathways
12.32 CASP3 CCND1 CDK2 CDK4 RB1 TP53
23
Show member pathways
12.32 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
24
Show member pathways
12.31 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
25
Show member pathways
12.29 CASP3 CCND1 CDK2 CDK4 RB1 TP53
26 12.22 CASP3 CCND1 CDK2 CDK4 TP53
27 12.16 CASP3 CCND1 CDK2 CDK4 NF1 RB1
28 12.11 CCND1 CDKN2B RBL1 TP53
29
Show member pathways
12.1 CCND1 CDK2 CDK4 NF1
30 12.08 CDK2 CDKN2A RB1 TP53
31
Show member pathways
12.07 CCND1 CDK2 CDK4 RB1 RBL1 TP53
32 12.05 CASP3 CCND1 CDK2 CDK4 RB1 TP53
33 11.96 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
34 11.93 CCND1 CDK2 CDK4 RB1 TP53
35 11.91 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
36 11.9 CASP3 CCND1 CDK4
37 11.86 CDK2 CDK4 CDKN2B RBL1
38 11.82 CCND1 CDK4 CDKN2A RB1 TP53
39 11.77 CASP3 CCND1 CDK2 CDK4 CDKN2B RB1
40 11.76 CDK2 RB1 RBL1
41 11.75 CASP3 CDKN2A TP53
42
Show member pathways
11.75 CDK2 CDKN2A TP53
43 11.73 CDK2 CDKN2A RB1 TP53
44 11.72 CDK2 CDK4 RB1
45 11.68 BACE1 CASP3 CCND1 TP53
46 11.67 CCND1 CDKN2B RBL1
47 11.66 CCND1 CDKN2A RB1 TP53
48 11.62 CCND1 CDK4 NF1
49 11.59 CASP3 CCND1 TP53
50 11.58 CCND1 CDK2 CDK4 TP53

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.56 CDK2 CDK4 RB1 RBL1
2 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CCND1 CDK2 CDK4
3 chromatin GO:0000785 8.92 CDK4 MYCN RB1 RBL1
4 nucleus GO:0005634 10.03 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
5 nucleoplasm GO:0005654 10.02 CASP3 CCND1 CDK2 CDK4 CDKN2A KMT2D

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 CASP3 CDK4 CDKN2A NF1 TP53
2 negative regulation of gene expression GO:0010629 9.92 CDKN2B-AS1 MYCN RB1 RBL1
3 cell cycle GO:0007049 9.92 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
4 response to drug GO:0042493 9.91 BCHE CASP3 CCND1 CDK4 MGMT SST
5 cell cycle arrest GO:0007050 9.84 CDKN2A CDKN2B RB1 TP53
6 response to organic cyclic compound GO:0014070 9.83 CASP3 CCND1 IDH1 MGMT
7 response to organic substance GO:0010033 9.8 CASP3 CCND1 CDK4
8 response to glucocorticoid GO:0051384 9.77 BCHE CASP3 CCND1
9 negative regulation of protein kinase activity GO:0006469 9.76 CDKN2A NF1 NF2 RB1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.75 CDKN2B RB1 RBL1
11 positive regulation of neuron apoptotic process GO:0043525 9.74 BACE1 CASP3 NF1
12 response to steroid hormone GO:0048545 9.67 CCND1 IDH1 SST
13 negative regulation of cell-matrix adhesion GO:0001953 9.65 CDKN2A NF1 NF2
14 G1/S transition of mitotic cell cycle GO:0000082 9.65 CCND1 CDK2 CDK4 CDKN2A RB1
15 striated muscle cell differentiation GO:0051146 9.63 CASP3 RB1
16 replicative senescence GO:0090399 9.62 CDKN2A TP53
17 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 MYCN TP53
18 response to folic acid GO:0051593 9.59 BCHE MGMT
19 mitotic G1 DNA damage checkpoint GO:0031571 9.58 CCND1 CDK2 TP53
20 regulation of lipid kinase activity GO:0043550 9.55 RB1 RBL1
21 Ras protein signal transduction GO:0007265 9.55 CDK2 CDKN2A NF1 RB1 TP53
22 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.54 CDK4 CDKN2A CDKN2B
23 glial cell apoptotic process GO:0034349 9.51 CASP3 RB1
24 regulation of cell cycle GO:0051726 9.43 CCND1 CDK2 CDK4 NF2 RB1 RBL1
25 negative regulation of cell proliferation GO:0008285 9.23 BCHE CDKN2A CDKN2B NF1 NF2 RB1
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 CDKN2A CDKN2B KMT2D MYCN RB1 RBL1
27 cellular response to DNA damage stimulus GO:0006974 10.01 CASP3 CCND1 CDK2 MGMT TP53

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.72 BACE1 BCHE CCND1 RB1 TP53
2 transcription factor binding GO:0008134 9.65 CCND1 CDKN2A RB1 RBL1 TP53
3 RNA polymerase II regulatory region DNA binding GO:0001012 9.37 RB1 RBL1
4 disordered domain specific binding GO:0097718 9.33 CDKN2A RB1 TP53
5 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.13 CCND1 CDK2 CDK4
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CASP3 CDKN2A CDKN2B